+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clostridium difficile Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)

  • ID: 5134724
  • Report
  • June 2020
  • Region: Global
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 2

FEATURED COMPANIES

  • bioMerieux SA
  • Danaher Corp
  • DiaSorin SpA
  • Meridian Bioscience Inc
  • Pharos Capital Group LLC
  • MORE
Summary

Clostridium difficile Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Clostridium difficile Tests market for the year 2020 and beyond. Clostridium difficile is one of the major etiological agents for hospital acquired infections all over the world, especially in the US. The disease manifests itself in the form of prolonged Diarrhoea and pseudo membranous colitis, often in patients who have recently stayed at a healthcare facility and/or have been using antibiotics for a significant length of time.

Clostridium difficile Infection (CDI) occurs along with other comorbidities and frequently increases the length of stay in hospital, even after the primary disease has been cured. The Clostridium difficile Tests include Culture, Clostridium Difficile Toxin EIA, Glutamate dehydrogenase (GDH) EIA, NAAT, Dual Toxin and GDH EIA Tests.

Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Clostridium difficile Tests and evolving competitive landscape -
  • Insightful review of the key industry trends.
  • Annualized total Clostridium difficile Tests market revenue by segment and market outlooks from 2015-2030.
  • Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights -
  • Qualitative market specific information is available with global trends further broken down into regional trends. In addition the publisher's analysts provide unique country specific insights on the market.
  • SWOT analysis for Clostridium difficile Tests market.
  • Competitive dynamics insights and trends provided for Clostridium difficile Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
  • Country specific overview of the healthcare system.
  • Country specific reimbursement policies.
  • Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Danaher Corp, Pharos Capital Group, LLC , Meridian Bioscience Inc, bioMerieux SA, DiaSorin SpA and Others

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
  • CMO executives who must have deep understanding of the Clostridium difficile Tests market place to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy

The model will enable you to:
  • Understand the impact of COVID-19 on Clostridium difficile Tests market.
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving Clostridium difficile Tests market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Clostridium difficile Tests market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in the global and country-specific Clostridium difficile Tests market from 2015-2030.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 2
  • Danaher Corp
  • Pharos Capital Group LLC
  • Meridian Bioscience Inc
  • bioMerieux SA
  • DiaSorin SpA
Note: Product cover images may vary from those shown
Adroll
adroll